

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA 427 Insp GMP/GDP/IMP 427/15276-0019[H]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :

Regulation 331A of The Human Medicines Regulations 2012 (SI 2012/1916)

The competent authority of United Kingdom confirms the following :

The Manufacturer : ROSEMONT PHARMACEUTICALS LIMITED

Site address : ROSEMONT PHARMACEUTICALS LIMITED, ROSEMONT HOUSE, YORKDALE INDUSTRIAL PARK, BRAITHWAITE STREET, LEEDS, LS11 9XE, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA 427 in accordance with Regulation 17 of The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 20/06/2022 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

-
- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
 - (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

1. MANUFACTURING OPERATIONS

[1.2] Non-sterile products

[1.2.1] Non-Sterile Products (processing operations for the following dosage forms)

[1.2.1.6] Liquids for internal use

[1.2.1.17] Other non-sterile medicinal products

Manufacture of cytotoxic agents - Methotrexate disodium

[1.2.2] Batch certification

[1.5] Packaging

[1.5.1] Primary packaging

[1.5.1.6] Liquids for internal use

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.2] Microbiological: non-sterility

[1.6.3] Chemical/Physical

Restrictions or Remarks

The secondary packaging activities under the MIA(IMP) are restricted to open label study packaging only; no randomisation activities are authorised.

25/09/2023	Name and signature of the authorised person of the Competent Authority of United Kingdom
	Confidential
	Medicines and Healthcare products Regulatory Agency
	Tel : Confidential